Comprehensive pan-cancer analysis reveals LAMA5 as a prognostic biomarker associated with tumor immunity in human cancers, with experimental validation in uveal melanoma

​​Background LAMA5, encoding the laminin α5 chain, is a crucial component of the extracellular matrix implicated in cell adhesion, migration, and signaling. However, a systematic assessment of its pan-cancer prognostic and immunological roles remains elusive. Methods We conducted an integrative multi-omics analysis utilizing datasets from TCGA, GTEx, CPTAC, and cBioPortal to evaluate the expression landscape, genetic alterations, diagnostic and prognostic value, and association with tumor immunity of LAMA5 across 33 cancer types. Functional enrichment and pathway analyses were performed to decipher potential mechanisms. Correlations with immune cell infiltration, immunomodulator genes, and chemotherapeutic response were assessed. The biological functions of LAMA5 were further experimentally validated in uveal melanoma (UVM) cell lines through knockdown experiments. Results LAMA5 expression was dysregulated across multiple cancer types and was associated with clinicopathological features and survival outcomes in selected cancers, including UVM. Exploratory ROC analyses suggested tissue-level discriminatory potential in several cancers, particularly cholangiocarcinoma. LAMA5 expression was also associated with angiogenesis-, epithelial–mesenchymal transition-, inflammation-, and immune-related transcriptional features. Drug-response and CMap analyses identified exploratory pharmacological associations with LAMA5-related expression patterns. In vitro , LAMA5 knockdown significantly reduced the proliferative, migratory, and invasive capacities of UVM cells. Conclusion Our comprehensive pan-cancer study identifies LAMA5 as a prognostic biomarker associated with tumor progression and distinct immune microenvironment features across cancers. Functional experiments in UVM cells further support a tumor cell-intrinsic role for LAMA5 in proliferation, migration, and invasion. These findings highlight the biological and prognostic relevance of LAMA5 in UVM, while its therapeutic potential and possible immunoregulatory functions require further experimental validation.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-17
DOI
https://doi.org/10.3389/fonc.2026.1989435
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comprehensive pan-cancer analysis reveals LAMA5 as a prognostic biomarker associated with tumor immunity in human cancers, with experimental validation in uveal melanoma

Fangxia Zhang, Wenyan Fan, Yang Liu, Brian Rossmiller
3 links
Frontiers in Oncology
Cancer Immunotherapy and Biomarkers
article

Comprehensive pan-cancer analysis reveals LAMA5 as a prognostic biomarker associated with tumor immunity in human cancers, with experimental validation in uveal melanoma

Fangxia Zhang, Wenyan Fan, Yang Liu, Brian Rossmiller
article en

Abstract

​​Background LAMA5, encoding the laminin α5 chain, is a crucial component of the extracellular matrix implicated in cell adhesion, migration, and signaling. However, a systematic assessment of its pan-cancer prognostic and immunological roles remains elusive. Methods We conducted an integrative multi-omics analysis utilizing datasets from TCGA, GTEx, CPTAC, and cBioPortal to evaluate the expression landscape, genetic alterations, diagnostic and prognostic value, and association with tumor immunity of LAMA5 across 33 cancer types. Functional enrichment and pathway analyses were performed to decipher potential mechanisms. Correlations with immune cell infiltration, immunomodulator genes, and chemotherapeutic response were assessed. The biological functions of LAMA5 were further experimentally validated in uveal melanoma (UVM) cell lines through knockdown experiments. Results LAMA5 expression was dysregulated across multiple cancer types and was associated with clinicopathological features and survival outcomes in selected cancers, including UVM. Exploratory ROC analyses suggested tissue-level discriminatory potential in several cancers, particularly cholangiocarcinoma. LAMA5 expression was also associated with angiogenesis-, epithelial–mesenchymal transition-, inflammation-, and immune-related transcriptional features. Drug-response and CMap analyses identified exploratory pharmacological associations with LAMA5-related expression patterns. In vitro , LAMA5 knockdown significantly reduced the proliferative, migratory, and invasive capacities of UVM cells. Conclusion Our comprehensive pan-cancer study identifies LAMA5 as a prognostic biomarker associated with tumor progression and distinct immune microenvironment features across cancers. Functional experiments in UVM cells further support a tumor cell-intrinsic role for LAMA5 in proliferation, migration, and invasion. These findings highlight the biological and prognostic relevance of LAMA5 in UVM, while its therapeutic potential and possible immunoregulatory functions require further experimental validation.

Frontiers in OncologyVol. 16
Buck Institute for Research on Aging (US), Ningxia Hui Autonomous Region Peoples Hospital (CN), Ningxia Medical University (CN), Ningxia Medical University General Hospital (CN), The Fourth People's Hospital of Ningxia Hui Autonomous Region (CN)
Ningxia Medical University
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon